The most common grade 3–4 adverse events were palmar-plantar erythrodysesthesia, back pain, and increased aspartate aminotransferase, each in 17% of patients, as well as thromboembolic events, hypertension, fatigue, and increased alanine aminotransferase, each in 11% of patients. This evidence concerns the gene GPT and hypertensive disorder.